Get the Stockscreener App
28.45
2.30%
0.64
Pre-market:
28.60
0.15
+0.53%
Alkermes Plc stock is traded at $28.45, with a volume of 4.28M.
It is up +2.30% in the last 24 hours and down -0.84% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.81
Open:
$27.91
24h Volume:
4.28M
Relative Volume:
1.84
Market Cap:
$4.70B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
14.59
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-0.18%
1M Performance:
-0.84%
6M Performance:
-3.00%
1Y Performance:
-5.07%
1-Day Range:
$27.82
$28.65
1-Week Range:
$27.53
$28.79
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.45 | 4.59B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
122.24 | 54.10B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 46.85B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.90 | 43.82B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.35 | 34.79B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
517.13 | 21.83B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Why analysts are rating Alkermes (ALKS) a buy - MSN
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Alkermes plc stock split attract more investors2025 Earnings Impact & Proven Capital Preservation Tips - ulpravda.ru
Is Alkermes plc stock positioned for digital transformationJuly 2025 Update & Reliable Intraday Trade Plans - ulpravda.ru
Is Alkermes plc (8AK) stock a top pick for value investors2025 Earnings Surprises & Low Risk Entry Point Tips - ulpravda.ru
Will Alkermes plc stock benefit from commodity pricesTrade Analysis Summary & Growth Focused Stock Pick Reports - ulpravda.ru
Why global investors buy Alkermes plc (8AK) stockEarnings Recap Report & Reliable Volume Spike Alerts - Bölüm Sonu Canavarı
Will Alkermes plc (8AK) stock test record highs in 20252025 Performance Recap & Low Risk Growth Stock Ideas - DonanımHaber
Can Alkermes plc stock continue upward trendPortfolio Gains Summary & Comprehensive Market Scan Reports - DonanımHaber
Bear Alert: Will Alkermes plc stock split attract more investorsOil Prices & Technical Pattern Alert System - ulpravda.ru
Behavioral Patterns of ALKS and Institutional Flows - news.stocktradersdaily.com
Is Alkermes plc (8AK) stock a momentum leaderTrade Risk Assessment & Real-Time Stock Entry Alerts - ulpravda.ru
How Alkermes plc (8AK) stock reacts to monetary easingBear Alert & Free Reliable Trade Execution Plans - ulpravda.ru
BlackRock increases stake in Alkermes to 17.04% - Investing.com
Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat
EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Retail Surge: Why global investors buy Alkermes plc 8AK stockCEO Change & Expert Curated Trade Ideas - moha.gov.vn
History Review: Will Alkermes plc 8AK stock test record highs in 2025Watch List & High Conviction Investment Ideas - moha.gov.vn
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com South Africa
BlackRock increases stake in Alkermes to 17% - Investing.com
REGBlackRock GroupSAR6ALKERMES PLC - TradingView — Track All Markets
Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN
Analyst Upgrade: How Alkermes plc stock performs after earningsQuarterly Risk Review & Reliable Intraday Trade Plans - moha.gov.vn
Stempoint Capital LP Acquires 158,772 Shares of Alkermes plc $ALKS - MarketBeat
First Trust Advisors LP Has $39.98 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes Plc (NASDAQ:ALKS)? - 富途牛牛
Alkermes, Avadel Pharmaceuticals merger gets HSR clearance in US - MLex
Avadel Pharmaceuticals Acquisition by Alkermes Advances - TradingView — Track All Markets
Are Investors Undervaluing Alkermes (ALKS) Right Now? - sharewise.com
(ALKS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Schroder Investment Management Group Invests $1.39 Million in Alkermes plc $ALKS - MarketBeat
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 3,748 Shares of Stock - MarketBeat
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN
Norges Bank Invests $53.33 Million in Alkermes plc $ALKS - MarketBeat
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
VP Hopkinson Sells 3,748 ($112.4K) Of Alkermes PLC [ALKS] - TradingView — Track All Markets
Avadel Pharmaceuticals plc and Alkermes plc Announce Proposed Transaction for Acquisition - Quiver Quantitative
Announcement relating to despatch of Rule 15 proposal - The Manila Times
Avadel (NASDAQ: AVDL) sends Rule 15 proposal to equity holders in Alkermes deal - Stock Titan
Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS - MarketBeat
Will Alkermes plc (8AK) stock sustain bullish trend into 2025Fed Meeting & Smart Money Movement Tracker - Newser
ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView
Avadel Pharmaceuticals Announces Mailing of Definitive Proxy Statement Regarding Proposed Acquisition by Alkermes - Quiver Quantitative
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Benzinga
Avadel (Nasdaq: AVDL) mails proxy, sets Jan. 12 scheme and EGM on Alkermes deal - Stock Titan
VP Hopkinson Files To Sell 3,748 Of Alkermes PLC [ALKS] - TradingView
Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat
Evercore Healthcare Conference - marketscreener.com
How Alkermes plc (8AK) stock valuation compares with sectorQuarterly Profit Report & Daily Profit Focused Screening - Newser
Is Alkermes plc (8AK) stock a safe buy pre earningsMarket Growth Summary & Real-Time Sentiment Analysis - Newser
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.70%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):